Bronchiectasis is one of the most neglected chronic lung diseases despite the fact it impacts 300,000 people in the UK ...

The number of patients with asthma was higher among those with bronchiectasis and situs inversus totalis vs. those without PCD in both the INPCR group (9 patients vs. 1 patient; P < .001) and the ...

Researchers have found in a new study over a 15-year follow-up that adults with asthma showed significantly higher rates of ...

The phase III ASPEN trial included 1,721 participants with bronchiectasis treated at 391 sites in 35 countries from November 2020 through March 2023. ... and 18.7% a history of asthma.

Former miners are among the patients being given a new lease of life by an NHS exercise and rehab class for people with ...

This updated asthma guideline establishes a consistent approach to improving asthma diagnosis and control in adults and children in the UK.

Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, ... while phase 2 results in bronchiectasis should come in 2026. Image. Phil Taylor. 15 April, 2025. asthma. Bookmark this.

Bronchiectasis impacts up to 500,000 Americans, but there is often misdiagnosis or delayed diagnosis as the condition can present similarly to other pulmonary conditions such as COPD or asthma.

Bronchiectasis is a condition that damages the lungs and airways, causing the body to produce a lot of phlegm, which can cause a range of other issues. As a result, it has some peculiar symptoms that ...

Itepekimab expanding into chronic rhinosinusitis along with COPD and bronchiectasis; phase 3 readouts in COPD in H2 2025 and bronchiectasis in 2026 Paris , April 15, 2025 .

Sanofi reports amlitelimab improved lung function in asthma, ... Finally, itepekimab is being explored in a phase 2 study in bronchiectasis, with the readout anticipated in 2026.

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory ...